Young Kwon, Ph.D.

Young is an Advisor to LSV. He assists the LSV biopharmaceutical team with deal sourcing, due diligence, and portfolio company management. He initially joined LSV in April 2021 as an Operating Partner.

Young is an accomplished executive with significant operating and venture capital experience.

He is currently the CEO of Alchemab Therapeutics, an LSV portfolio company focused on developing novel antibody therapeutics generated from patients resilient to disease.

Young is also a member of the board of directors of ADMA Biologics, (Nasdaq: ADMA), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics.

Young held a variety of leadership roles over ten years as a senior executive at Momenta Pharmaceuticals, a public biotech company, prior to its sale to Johnson & Johnson for $6.5 billion. Young was most recently Chief Financial and Business Officer at Momenta, where he had responsibility for business development, strategy, finance, investor relations, and commercial. Young led public equity financings raising nearly $500 million, and led the company’s sale to J&J. Prior to Momenta, Young was a business development professional at Biogen, driving a variety of transactions. Young previously worked at Advanced Technology Ventures, working with the team on investments including Acceleron, Five Prime, Hypnion, and Zeltiq.

Doug Treco, Ph.D.

Doug Treco, PhD, was a co-founder of Ra Pharmaceuticals, Inc. in 2008 and served as Chief Executive Officer and a member of the Board of Directors from its inception until its acquisition by UCB in April 2020. Previously, he was an Entrepreneur-in-Residence at Morgenthaler Ventures from January 2008 to May 2014. In 1988, he co-founded Transkaryotic Therapies Inc. (TKT), a multi-platform biopharmaceutical company developing protein and gene therapy products, which was acquired by Shire Pharmaceuticals Group plc in 2005.  Dr. Treco was a Visiting Scientist in the Department of Molecular Biology at Massachusetts General Hospital and a Lecturer in Genetics at Harvard Medical School from 2004 to 2007. He received his Ph.D. in Biochemistry and Molecular Biology from the State University of New York at Stony Brook and performed postdoctoral studies at the Salk Institute for Biological Studies and Massachusetts General Hospital.

Jaume Pons, Ph.D.

Dr. Pons currently serves as the President and Chief Executive Officer of ALX Oncology. He previously served as Chief Scientific Officer and site head of Rinat (Pfizer), where he was responsible for portfolio delivery from idea to clinical development. He implemented the vision of a company unit following biology across therapeutic areas while generating advanced antibody technologies and turned Rinat into the center of cancer immunology for Pfizer. Dr. Pons is an inventor of fremanezumab, which was approved by the FDA in 2018, as well as two other antibodies in late-stage clinical development and has advanced nine additional antibodies into human trials in multiple therapeutic areas. As Senior Vice President of R&D, he was a member of Pfizer’s World R&D Leadership Team. Before Pfizer, Dr. Pons created and led Rinat’s protein engineering group and was a scientist at Chiron.

Stacy Enxing Seng

Stacy is an Operating Partner of LSV and assists the LSV medical device team with deal sourcing, due diligence, and portfolio company management. She joined the LSV team in March 2016.

Since 2013, Stacy has also focused her work on engaging as a Professional Director, serving as an Independent Director and Committee Member for both public and venture-backed private companies across the healthcare ecosystem. Stacy currently serves as a non-executive Independent Director and member of the Compensation and Management Committee for Hill-Rom Holdings, Inc. (NYSE: HRC), Sonova Holding AG (VTX: SOON), and LivaNova, Inc. (NASDAQ: LIVN). Stacy also serves as Chairwoman of the Board for both CALA Health and Contego, an Independent Director for Vesper Medical, as well as a Director for the Fogarty Institute, a non-profit educational innovator. Past Director appointments include PreCARDIA Inc, (exited to Abiomed), Claret Inc, (exited to Boston Scientific), Spirox, (exited to Entellus/Abbott) FIRE 1, (Covidien/Medtronic Investment), CVI (exited to Covidien/Medtronic) and Solace Therapeutics.

An accomplished executive leader, Stacy has over 25 years in sales, marketing and operational leadership roles building innovative technology portfolios, demonstrated clinical outcomes, exceptional management teams and world-class company cultures. She has been recognized as one of the Top 100 Women in Business and is a frequent speaker on healthcare, innovation leadership and corporate culture.

Prior to Independent Director work, Stacy served as the President of Covidien’s $1.7B Vascular Therapies business. Stacy joined Covidien following its $2.6B acquisition of ev3 Inc., a medical technology start-up that Stacy co-created in 2000 with ev3’s founding team. Over the course of her career, Stacy has been involved in the launch of over 20 medtech technologies, more than 10 substantive M&A transactions, and under her operating leadership, a reputation of achieving world class customer and employee

Stacy’s earlier work in medtech included sales and marketing leadership roles with SCIMED/Boston Scientific and sales and product management roles with American Hospital Supply/Baxter.